These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 25002733)

  • 1. Complete cytogenetic response, not deep molecular response, is associated with survival in chronic myeloid leukemia.
    Kantarjian H; Cortes JE
    J Clin Oncol; 2014 Sep; 32(27):3077. PubMed ID: 25002733
    [No Abstract]   [Full Text] [Related]  

  • 2. What does a deep molecular response signify?
    Politi J; Shah NP
    J Clin Oncol; 2014 Feb; 32(5):471-4. PubMed ID: 24297955
    [No Abstract]   [Full Text] [Related]  

  • 3. Haematological cancer: Deep molecular response predicts survival in CML.
    Razzak M
    Nat Rev Clin Oncol; 2014 Feb; 11(2):68. PubMed ID: 24343665
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to H. Kantarjian et al.
    Hehlmann R; Hasford J; Pfirrmann M; Lauseker M; Saußele S; Hochhaus A; ;
    J Clin Oncol; 2014 Sep; 32(27):3078-9. PubMed ID: 25002729
    [No Abstract]   [Full Text] [Related]  

  • 5. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?
    Richter J; Söderlund S; Lübking A; Dreimane A; Lotfi K; Markevärn B; Själander A; Saussele S; Olsson-Strömberg U; Stenke L
    J Clin Oncol; 2014 Sep; 32(25):2821-3. PubMed ID: 25071107
    [No Abstract]   [Full Text] [Related]  

  • 6. VEGF in chronic myeloid leukemia treated with interferon and imatinib.
    Aguayo A
    Leuk Res; 2014 Jun; 38(6):660-1. PubMed ID: 24726782
    [No Abstract]   [Full Text] [Related]  

  • 7. PPARγ ligands increase antileukemic activity of second- and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia cells.
    Glodkowska-Mrowka E; Manda-Handzlik A; Stelmaszczyk-Emmel A; Seferynska I; Stoklosa T; Przybylski J; Mrowka P
    Blood Cancer J; 2016 Jan; 6(1):e377. PubMed ID: 26745851
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to J. Richter et al.
    Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
    J Clin Oncol; 2014 Sep; 32(25):2823-5. PubMed ID: 25071119
    [No Abstract]   [Full Text] [Related]  

  • 9. Hydroxychloroquine for chronic myeloid leukemia: complete cure on the horizon?
    Mukhopadhyay A; Helgason GV; Karvela M; Holyoake TL
    Expert Rev Hematol; 2011 Aug; 4(4):369-71. PubMed ID: 21801126
    [No Abstract]   [Full Text] [Related]  

  • 10. Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects.
    Neelakantan P; Rezvani K; May P; Gerrard G; Marco B; Paliompeis C; Reid A; Goldman J; Marin D; Milojkovic D
    Br J Haematol; 2014 Feb; 164(4):608-10. PubMed ID: 24219400
    [No Abstract]   [Full Text] [Related]  

  • 11. Cancer: Repositioned to kill stem cells.
    Holyoake T; Vetrie D
    Nature; 2015 Sep; 525(7569):328-9. PubMed ID: 26331538
    [No Abstract]   [Full Text] [Related]  

  • 12. Chemotherapy and imatinib-induced molecular remission in lymphoid blast crisis after 20 years of "untreated" chronic myeloid leukemia.
    Koca E; Sevimli F; Cetiner D; Haznedaroglu IC; Sayinalp N; Büyükasik Y; Goker H; Ozcebe O
    Am J Hematol; 2007 Apr; 82(4):333. PubMed ID: 17094091
    [No Abstract]   [Full Text] [Related]  

  • 13. Haematological cancer: Repositioned to attack CML cells.
    Killock D
    Nat Rev Clin Oncol; 2015 Nov; 12(11):624. PubMed ID: 26391777
    [No Abstract]   [Full Text] [Related]  

  • 14. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.
    Eskazan AE; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
    Leuk Lymphoma; 2014 Dec; 55(12):2935-7. PubMed ID: 24650055
    [No Abstract]   [Full Text] [Related]  

  • 15. Chronic myeloid leukemia: where do we go now?
    Cortés JE
    Clin Lymphoma Myeloma; 2009; 9 Suppl 4():S374-5. PubMed ID: 20007105
    [No Abstract]   [Full Text] [Related]  

  • 16. PPARγ: Welcoming the New Kid on the CML Stem Cell Block.
    Apsel Winger B; Shah NP
    Cancer Cell; 2015 Oct; 28(4):409-411. PubMed ID: 26461088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era.
    Malagola M; Breccia M; Skert C; Cancelli V; Soverini S; Iacobucci I; Cattina F; Liberati AM; Tiribelli M; Annunziata M; Trabacchi E; De Vivo A; Castagnetti F; Martinelli G; Fogli M; Stagno F; Pica G; Iurlo A; Pregno P; Abruzzese E; Pardini S; Bocchia M; Russo S; Pierri I; Lunghi M; Barulli S; Merante S; Mandelli F; Alimena G; Rosti G; Baccarani M; Russo D
    Am J Hematol; 2014 Feb; 89(2):119-24. PubMed ID: 24122886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line therapy for patients with chronic myeloid leukemia resistant to first-line imatinib.
    Lau A; Seiter K
    Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):186-96. PubMed ID: 24456839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when is this a safe option to consider?
    Sweet K; Oehler V
    Hematology Am Soc Hematol Educ Program; 2013; 2013():184-8. PubMed ID: 24319180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tyrosine kinase inhibitors for the treatment of CML].
    Heim D
    Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.